Literature DB >> 20697956

Thymoquinone-induced Neu4 sialidase activates NFκB in macrophage cells and pro-inflammatory cytokines in vivo.

Trisha M Finlay1, Samar Abdulkhalek, Alanna Gilmour, Christina Guzzo, Preethi Jayanth, Schammim Ray Amith, Katrina Gee, Rudi Beyaert, Myron R Szewczuk.   

Abstract

Thymoquinone (TQ) derived from the nutraceutical black cumin oil has been reported to be a novel agonist of Neu4 sialidase activity in live cells (Glycoconj J DOI 10.1007/s10719-010-9281-6). The activation of Neu4 sialidase on the cell surface by TQ was found to involve GPCR-signaling via membrane targeting of Gαi subunit proteins and matrix metalloproteinase-9 activation. Contrary to other reports, TQ had no anti-inflammatory effects in vitro. Here, we show that MyD88/TLR4 complex formation and subsequent NFκB activation are induced by the Neu4 activity associated with TQ-stimulated live primary bone marrow (BM) macrophage cells from WT and Neu1-deficient mice, HEK-TLR4/MD2 cells and BMC-2 macrophage cell line but not with primary macrophage cells from Neu4-knockout mice. Tamiflu (oseltamivir phosphate), pertussis toxin (PTX), a specific inhibitor of Gαi proteins of G-protein coupled receptor (GPCR) and the broad range inhibitor of matrix metalloproteinase (MMP) galardin applied to live primary BM macrophage cells completely block TQ-induced MyD88/TLR4 complex formation. Using immunocytochemistry and western blot analyses, Tamiflu, galardin and PTX inhibit NFκB activation induced by Neu4 activity associated with TQ-stimulated BMC-2 cells, HEK-TLR4/MD2 cells and primary BM macrophages from WT mice. EMSA analyses on HEK-TLR4/MD2 nuclear cell extracts confirm the nuclear localization and DNA binding of TQ-induced NFκB activation in a biphasic manner within 30 min. Co-immunoprecipitation experiments reveal for the first time that MMP-9 may be an important intermediate link in the TQ-induced Neu4 activity circuitously targeting TLR4 receptors. Central to this process is that Neu4 forms a complex with MMP-9, which is already bound to TLR4 receptors. Fluorescence spectrophotometer analyses of live CD14-THP1 cells treated with TQ show Neu4 sialidase activity over 5 min. Using flow cytometry analyses, CD14-THP1 cells treated with TQ express stable protein levels of Neu4, TLR4 and MMP9 on the cell surface over 30 min except for a marked diminution of MMP9 at 15 min. Using cytokine array profiling analyses of serum, Neu4-knockout mice respond poorly to TQ in producing pro-inflammatory cytokines and chemokines after 5-h treatment compared to the wild-type or hypomorphic cathepsin A mice with a secondary 90% Neu1 deficient mice. Our findings establish an unprecedented signaling paradigm for TQ-induced Neu4 sialidase activity. It signifies that MMP-9 forms an important molecular signaling platform in complex with TLR4 receptors at the ectodomain and acts as the intermediate link for TQ-induced Neu4 sialidase in generating a functional receptor with subsequent NFκB activation and pro-inflammatory cytokine production in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697956     DOI: 10.1007/s10719-010-9302-5

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  38 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

3.  Downregulation of leukotriene biosynthesis by thymoquinone attenuates airway inflammation in a mouse model of allergic asthma.

Authors:  Mohamed El Gazzar; Rabab El Mezayen; Mark R Nicolls; John C Marecki; Stephen C Dreskin
Journal:  Biochim Biophys Acta       Date:  2006-03-31

4.  Neu1 sialidase and matrix metalloproteinase-9 cross-talk is essential for neurotrophin activation of Trk receptors and cellular signaling.

Authors:  Preethi Jayanth; Schammim Ray Amith; Katrina Gee; Myron R Szewczuk
Journal:  Cell Signal       Date:  2010-03-25       Impact factor: 4.315

5.  Dissecting the epidermal growth factor receptor signal transactivation pathway.

Authors:  Oliver M Fischer; Stefan Hart; Axel Ullrich
Journal:  Methods Mol Biol       Date:  2006

6.  An efficient culture method for generating large quantities of mature mouse splenic macrophages.

Authors:  Attiya Alatery; Sameh Basta
Journal:  J Immunol Methods       Date:  2008-08-26       Impact factor: 2.303

7.  Human sialidase NEU4 long and short are extrinsic proteins bound to outer mitochondrial membrane and the endoplasmic reticulum, respectively.

Authors:  Alessandra Bigi; Lavinia Morosi; Chiara Pozzi; Matilde Forcella; Guido Tettamanti; Bruno Venerando; Eugenio Monti; Paola Fusi
Journal:  Glycobiology       Date:  2009-09-30       Impact factor: 4.313

8.  Neu1 desialylation of sialyl alpha-2,3-linked beta-galactosyl residues of TOLL-like receptor 4 is essential for receptor activation and cellular signaling.

Authors:  Schammim Ray Amith; Preethi Jayanth; Susan Franchuk; Trisha Finlay; Volkan Seyrantepe; Rudi Beyaert; Alexey V Pshezhetsky; Myron R Szewczuk
Journal:  Cell Signal       Date:  2009-09-29       Impact factor: 4.315

9.  Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1.

Authors:  Volkan Seyrantepe; Aleksander Hinek; Junzheng Peng; Michael Fedjaev; Sheila Ernest; Yoshito Kadota; Maryssa Canuel; Kohji Itoh; Carlos R Morales; Julie Lavoie; Johanne Tremblay; Alexey V Pshezhetsky
Journal:  Circulation       Date:  2008-04-07       Impact factor: 29.690

10.  Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells.

Authors:  Volkan Seyrantepe; Karine Landry; Stéphanie Trudel; Jacob A Hassan; Carlos R Morales; Alexey V Pshezhetsky
Journal:  J Biol Chem       Date:  2004-06-22       Impact factor: 5.157

View more
  7 in total

1.  Sialidase neu4 deficiency is associated with neuroinflammation in mice.

Authors:  Zehra Kevser Timur; Orhan Kerim Inci; Secil Akyildiz Demir; Volkan Seyrantepe
Journal:  Glycoconj J       Date:  2021-10-23       Impact factor: 2.916

2.  Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase.

Authors:  Kazunori Yamaguchi; Kazuhiro Shiozaki; Setsuko Moriya; Koichi Koseki; Tadashi Wada; Hiroo Tateno; Ikuro Sato; Masahide Asano; Yoichiro Iwakura; Taeko Miyagi
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

3.  Nigella sativa (black cumin) seed extract alleviates symptoms of allergic diarrhea in mice, involving opioid receptors.

Authors:  Swantje C Duncker; David Philippe; Christine Martin-Paschoud; Mireille Moser; Annick Mercenier; Sophie Nutten
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

4.  Anti-influenza neuraminidase inhibitor oseltamivir phosphate induces canine mammary cancer cell aggressiveness.

Authors:  Joana T de Oliveira; Ana L Santos; Catarina Gomes; Rita Barros; Cláudia Ribeiro; Nuno Mendes; Augusto J de Matos; M Helena Vasconcelos; Maria José Oliveira; Celso A Reis; Fátima Gärtner
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

5.  Sialylation transmogrifies human breast and pancreatic cancer cells into 3D multicellular tumor spheroids using cyclic RGD-peptide induced self-assembly.

Authors:  Roman Akasov; Sabah Haq; Fiona Haxho; Vanessa Samuel; Sergey V Burov; Elena Markvicheva; Ronald J Neufeld; Myron R Szewczuk
Journal:  Oncotarget       Date:  2016-10-04

6.  Mammalian Neuraminidases in Immune-Mediated Diseases: Mucins and Beyond.

Authors:  Erik P Lillehoj; Irina G Luzina; Sergei P Atamas
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

Review 7.  Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis.

Authors:  Fiona Haxho; Ronald J Neufeld; Myron R Szewczuk
Journal:  Oncotarget       Date:  2016-06-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.